Cisplatinum

Phase 2Small molecule

TThe Netherlands Cancer Institute

Cisplatinum is one of 45 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Oropharyngeal CarcinomaRecruiting

LymphomaPreclinical

Active, not recruiting

Oropharyngeal CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cisplatinum

TThe Netherlands Cancer Institute

Phase 2

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Oropharyngeal Carcinoma

NCT03215719

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Completed·RRoyal Marsden NHS Foundation Trust··NCT00301301·39 enrolled

Mantle Cell Lymphoma1 trial

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02896582·86 enrolled

Non-Small Cell Lung Cancer1 trial

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT00379717·30 enrolled

Clinical Efficacy and Safety1 trial

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Unknown status·SShenzhen Hornetcorn Bio-technology Company, LTD·Phase 2·NCT02766348·60 enrolled

Head and Neck Cancer1 trial

Adaptive Radiation Treatment for Head and Neck Cancer

Completed·TThe Netherlands Cancer Institute·Phase 3·NCT01504815·268 enrolled

5 more indications

Locally Advanced Head and Neck Cancer1 trial

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

Unknown status·GGeorge Washington University·Phase 2·NCT02760667·20 enrolled

Efficacy1 trial

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209222·360 enrolled

Dendritic Cell1 trial

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Completed·UUniversity of Arkansas·Phase 2·NCT00083538·40 enrolled

Oropharyngeal Carcinoma1 trial

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

Recruiting·NNYU Langone Health·Phase 2·NCT03215719·120 enrolled

Cisplatin1 trial

Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC

Unknown status·UUniversität Duisburg-Essen·Phase 2·NCT01742767

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Cisplatinum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatinum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatinum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Netherlands Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe Netherlands Cancer Institute

Cisplatinum

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Lymphoma1 trial

Mantle Cell Lymphoma1 trial

Non-Small Cell Lung Cancer1 trial

Clinical Efficacy and Safety1 trial

Head and Neck Cancer1 trial

Locally Advanced Head and Neck Cancer1 trial

Efficacy1 trial

Dendritic Cell1 trial

Oropharyngeal Carcinoma1 trial

Cisplatin1 trial

References

Drug Info

Quick Facts

Related News